Sugi Predict

Sugi Predict / Compounds / SCHEMBL2465547

SCHEMBL2465547

SCHEMBL2465547

CC(C)(OC(N)=O)c1ccccn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ MAPK1 P28482 1/20 0.43
▸ NPC1 O15118 1/20 0.41
▸ TP53 P04637 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ BLM P54132 2/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ SLC22A2 O15244 1/20 0.40
▸ SLC22A1 O15245 1/20 0.40
▸ PGR P06401 1/20 0.40
▸ THRB P10828 1/20 0.40
▸ ADRB3 P13945 1/20 0.40
▸ OPRK1 P41145 1/20 0.40
▸ PMP22 Q01453 1/20 0.40
▸ KCNH2 Q12809 1/20 0.40
▸ PDE3A Q14432 1/20 0.40
▸ SLC47A1 Q96FL8 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ ALOX15 P16050 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21742157 0.84 L3MBTL1 (0.47) SMN1; SMN2L3MBTL1MAPK1NPC1TP53
SCHEMBL29137044 0.83 SMN1; SMN2 (0.43) SMN1; SMN2L3MBTL1MAPK1NPC1TP53
SCHEMBL476472 0.83 SMN1; SMN2 (0.43) SMN1; SMN2L3MBTL1MAPK1NPC1TP53
SCHEMBL31239295 0.81 SMN1; SMN2 (0.44) SMN1; SMN2L3MBTL1NPC1TP53RAB9A
SCHEMBL14062725 0.80 TSHR (0.45) SMN1; SMN2L3MBTL1MAPK1NPC1RAB9A
SCHEMBL8283520 0.77 MAPT (0.52) SMN1; SMN2L3MBTL1MAPK1NPC1TP53
SCHEMBL13527864 0.76 BLM (0.44) SMN1; SMN2L3MBTL1NPC1TP53RAB9A
SCHEMBL7454285 0.75 SMN1; SMN2 (0.52) SMN1; SMN2L3MBTL1MAPK1NPC1RAB9A
SCHEMBL28996600 0.75 SMN1; SMN2 (0.48) SMN1; SMN2L3MBTL1MAPK1NPC1TP53
SCHEMBL18765714 0.75 SMN1; SMN2 (0.44) SMN1; SMN2L3MBTL1MAPK1NPC1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113557017-B Inhibitors of cyclin-dependent kinase 7 and uses thereof 丹娜-法伯癌症研究院 2024-11-29 — — CN disclosed
US-20240166666-A1 ANTITUMORAL COMPOUNDS PHARMA MAR SA (ES) 2024-05-23 — — US disclosed
US-20240131180-A1 DRUG ANTIBODY CONJUGATES PHARMA MAR, S.A. (ES) 2024-04-25 — — US disclosed
EP-4025253-B1 DRUG ANTIBODY CONJUGATES PHARMA MAR SA (ES) 2024-03-20 — — EP disclosed
EP-4101855-B9 ANTITUMORAL COMPOUNDS PHARMA MAR SA (ES) 2024-01-03 — — EP disclosed
EP-3615544-B9 ANTITUMORAL COMPOUNDS PHARMA MAR SA (ES) 2024-01-03 — — EP disclosed
EP-4101855-B1 ANTITUMORAL COMPOUNDS PHARMA MAR SA (ES) 2023-08-02 — — EP disclosed
US-11713325-B2 Antitumoral compounds PHARMA MAR, S.A. (ES) 2023-08-01 — — US disclosed
US-20230218774-A1 DRUG ANTIBODY CONJUGATES PHARMA MAR, S.A. (ES) 2023-07-13 — — US disclosed
WO-2023067132-A1 ANTITUMORAL COMPOUNDS PHARMA MAR, S.A. (ES) 2023-04-27 — — WO disclosed
WO-2021043951-A1 DRUG ANTIBODY CONJUGATES PHARMA MAR, S.A. (ES) 2021-03-11 — — WO disclosed
US-10538535-B2 Antitumoral compounds PHARMA MAR, S.A. (ES) 2020-01-21 — — US disclosed
US-10442820-B2 — — 2019-10-15 — — US disclosed
US-20180312529-A1 Antitumoral Compounds PHARMA MAR, S.A. (ES) 2018-11-01 — — US disclosed
WO-2014060575-A2 PROCESS FOR THE ENANTIOSELECTIVE SYNTHESIS OF A TETRAHYDROBENZAZEPINE COMPOUND MEDICHEM S.A. (ES) 2014-04-24 — — WO disclosed
US-20130345192-A1 HETEROCYCLIC TYROSINE KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. (US) 2013-12-26 — — US disclosed
US-8536293-B2 Biomaterial VYSERA BIOMEDICAL LIMITED (IE) 2013-09-17 — — US disclosed
EP-2632898-A1 HETEROCYCLIC TYROSINE KINASE INHIBITORS Biogen Idec MA Inc. (US) 2013-09-04 — — EP disclosed
WO-2012058645-A1 HETEROCYCLIC TYROSINE KINASE INHIBITORS BIOGEN IDEC MA INC. (US) 2012-05-03 — — WO disclosed
US-20110224321-A1 Biomaterial VYSERA BIOMEDICAL LIMITED (IE) 2011-09-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10538535-B2 Antitumoral compounds TP53, RB1, XPOT SMN1; SMN2 2945/4885L3MBTL1 1130/4885MAPK1 4210/4885
US-20240131180-A1 DRUG ANTIBODY CONJUGATES STT3B, STT3A, TTL SMN1; SMN2 3089/4885L3MBTL1 404/4885MAPK1 3187/4885
US-10442820-B2 — RPS4X, RPS4Y1, XPOT SMN1; SMN2 2686/4885L3MBTL1 1096/4885MAPK1 4415/4885
US-20240166666-A1 ANTITUMORAL COMPOUNDS TP53, TOP1, MCL1 SMN1; SMN2 2847/4885L3MBTL1 4215/4885MAPK1 3123/4885
US-20180312529-A1 Antitumoral Compounds TP53, RB1, XPOT SMN1; SMN2 2945/4885L3MBTL1 1130/4885MAPK1 4210/4885
US-11713325-B2 Antitumoral compounds TP53, TOP1, MCL1 SMN1; SMN2 2847/4885L3MBTL1 4215/4885MAPK1 3123/4885
US-20130345192-A1 HETEROCYCLIC TYROSINE KINASE INHIBITORS TEC, ABL1, LCK SMN1; SMN2 4612/4885L3MBTL1 2201/4885MAPK1 302/4885
US-20230218774-A1 DRUG ANTIBODY CONJUGATES B3GAT3, MGAT3, SDAD1 SMN1; SMN2 4523/4885L3MBTL1 268/4885MAPK1 2403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.